CDC Update on Pertussis Surveillance and Tdap Vaccine Recommendations

Abstract

Pertussis is the most poorly controlled bacterial vaccine-preventable disease. Since the early 1980s there has been an increase in reported cases of pertussis. Multiple factors have likely contributed to the increase, including waning immunity, increased recognition, and changes in diagnostic testing and reporting. Of the four combination vaccines used to prevent diphtheria, tetanus, and pertussis, one dose of Tdap should be used to vaccinate preteens as well as teens and adults who have not yet received this booster dose. It is the position of NASN that immunizations, including the Tdap vaccine, are key to primary prevention of disease from infancy through adulthood. The school nurse is in a critical position to create awareness and influence action-related national and state recommendations for the Tdap vaccine.

Keywords

pertussis Tdap immunizations vaccines preteens teens

Get full access to this article

View all access options for this article.

References

American Nurses Association & NASN. (2011). Scope and standards of practice: School nursing (2nd ed.). Silver Spring, MD: Nursesbooks.org.

Centers for Disease Control and Prevention. (1997). Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 46(RR7), 1-25.

Centers for Disease Control and Prevention. (2005). Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis. Morbidity and Mortality Weekly Report, 54(RR14), 1-16.

Centers for Disease Control and Prevention. (2006). Preventing tetanus, diphtheria, and pertussis among adolescents: Use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Morbidity and Mortality Weekly Report, 55(RR3), 1-34.

Centers for Disease Control and Prevention. (2011a). Immunization of health-care personnel. Morbidity and Mortality Weekly Report, 60(RR7), 1-45.

Centers for Disease Control and Prevention. (2011b). National and state vaccination coverage among adolescents aged 13 through 17 years—United States, 2010. Morbidity and Mortality Weekly Report, 60(33), 1117-1123.

Centers for Disease Control and Prevention. (2011c). Note to readers: Final 2010 reports of nationally notifiable infectious diseases. Morbidity and Mortality Weekly Report, 60(32), 1088-1101.

Centers for Disease Control and Prevention. (2011d). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2011. Morbidity and Mortality Weekly Report, 60(1), 13-15.

Centers for Disease Control and Prevention. (2011e). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine in pregnant women and persons who have or anticipate having close contact with an infant aged less than 12 months—Advisory Committee on Immunization Practices (ACIP), 2011. Morbidity and Mortality Weekly Report, 60(41), 1424-1426.

10.

Misegades

L. K.

Winter

Harriman

Talarico

Clark

Martin

(2011, October). DTaP effectiveness: Results from the California pertussis vaccine effectiveness assessment. Presented at the 49th annual meeting of the Infectious Diseases Society of America, Boston, MA.

11.

NASN. (2010). Position statement—Immunizations. Silver Spring, MD: NASN.

12.

Skoff

T. H.

Cohn

A. C.

Clark

T. A.

Messonnier

N. E.

Martin

S. W.

(2012). Early impact of the US Tdap vaccination program on pertussis trends. Archives of Pediatric and Adolescent Medicine, 166, 344-349. doi:10.1001/archpediatrics.2011.1093